Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash And Cash Equivalents At Carrying Value | 2 | 2 | 2 | 3 | 4 | 2 | 6 | 6 | 7 | 3 | 2 | 1 | |||||
Accounts Receivable Net Current | 1 | 2 | 2 | 2 | 2 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | |||||
Assets Current | |||||||||||||||||
Assets Current | 4 | 5 | 4 | 6 | 7 | 4 | 7 | 7 | 8 | 4 | 2 | 2 | |||||
Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | |||||
Assets Noncurrent | |||||||||||||||||
Goodwill | 9 | 9 | 9 | 8 | 8 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | |||||
Property Plant And Equipment Net | 4 | 4 | 4 | 6 | 5 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | |||||
Operating Lease Right Of Use Asset | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Intangible Assets Net Excluding Goodwill | 4 | 4 | 4 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Deposits Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Assets | 24 | 25 | 25 | 26 | 26 | 11 | 15 | 15 | 16 | 12 | 11 | 10 | |||||
Liabilities And Stockhold… | |||||||||||||||||
Accounts Payable Current | 3 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | |||||
Accrued Liabilities Current | 7 | 6 | 6 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | |||||
Contract With Customer Liability Current | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | |||||
Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Liabilities Current | |||||||||||||||||
Liabilities Current | 20 | 18 | 18 | 7 | 6 | 5 | 5 | 5 | 7 | 8 | 7 | 7 | |||||
Finance Lease Liability Current | - | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | |||||
Long Term Debt Current | 8 | 7 | 8 | 0 | 0 | - | - | - | - | - | - | - | |||||
Other Liabilities Current | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Liabilities Noncurrent | |||||||||||||||||
Contract With Customer Liability Noncurrent | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | |||||
Operating Lease Liability Noncurrent | 3 | 4 | 4 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | |||||
Finance Lease Liability Noncurrent | - | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | |||||
Long Term Debt Noncurrent | 0 | 0 | 0 | 8 | 8 | - | - | - | - | - | - | - | |||||
Other Liabilities Noncurrent | 1 | 1 | 1 | 1 | 1 | - | - | - | - | - | - | - | |||||
Liabilities | 28 | 26 | 27 | 23 | 21 | 7 | 7 | 8 | 9 | 11 | 10 | 10 | |||||
Common Stock Value | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | 0 | |||||
Stockholders Equity | |||||||||||||||||
Additional Paid In Capital | 134 | 132 | 124 | 121 | 118 | 112 | 112 | 109 | 105 | 97 | 93 | 89 | |||||
Stockholders Equity | -4 | -1 | -2 | 3 | 5 | 4 | 8 | 8 | 6 | 1 | 0 | 0 | |||||
Retained Earnings Accumulated Deficit | -139 | -133 | -125 | -118 | -113 | -108 | -104 | -101 | -99 | -97 | -93 | -89 | |||||
Minority Interest | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | |||||
Liabilities And Stockholders Equity | 24 | 25 | 25 | 26 | 26 | 11 | 15 | 15 | 16 | 12 | 11 | 10 | |||||
Allowance For Doubtful Accounts Receivable | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Authorized | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | |||||
Preferred Stock Shares Issued | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Outstanding | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | |||||
Common Stock Shares Issued | 15 | 13 | 9 | 8 | 7 | 6 | 6 | 5 | 3 | 3 | 2 | 1 | |||||
Shares Outstanding | 15 | 13 | 9 | 8 | 7 | 6 | 6 | 5 | 3 | 3 | 2 | 1 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -3.05% | -26.78% | -45.08% | - | - | - | - | - | - | - | - | - |
| 2025 | -27.12% | 44.77% | 69.28% | -18.74% | -26.93% | -39.81% | -12.29% | -12.71% | -34.32% | -54.76% | -41.16% | -69.18% |
| 2024 | -1.61% | -7.63% | -15.66% | 10.55% | 5.91% | 13.08% | 33.65% | 40.06% | 27.24% | -7.72% | -20.00% | -1.75% |
| 2023 | - | - | - | -25.66% | -18.95% | -60.12% | 310.46% | 150.13% | 64.34% | -43.69% | -52.59% | -53.42% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Metrics | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Metric history beyond 3 years is for subscribers only. Unlock 17+ years of history across 90+ calculated metrics Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liquidity Ratios | |||||||||||||||||
| Current Ratio | 0.21 | 0.27 | 0.24 | 0.78 | 1.05 | 0.77 | 1.50 | 1.44 | 1.18 | 0.45 | 0.34 | 0.28 | |||||
| Quick Ratio | 0.16 | 0.22 | 0.20 | 0.70 | 0.94 | 0.65 | 1.34 | 1.32 | 1.10 | 0.39 | 0.25 | 0.17 | |||||
| Working Capital | -16.18M | -13.12M | -13.69M | -1.65M | 304.00K | -1.09M | 2.50M | 2.27M | 1.21M | -4.46M | -4.83M | -5.18M | |||||
Leverage & Debt | |||||||||||||||||
| Debt to Equity | -7.06 | -23.12 | -17.92 | 9.13 | 4.68 | 1.56 | 0.92 | 1.00 | 1.50 | 19.28 | 25.11 | 223.28 | |||||
| Interest Coverage TTM | - | -225.91 | -198.94 | -163.22 | -142.33 | - | - | - | - | - | - | - | |||||
| Debt Ratio | 1.17 | 1.05 | 1.06 | 0.90 | 0.82 | 0.61 | 0.48 | 0.50 | 0.60 | 0.95 | 0.96 | 1.00 | |||||
Efficiency & Turnover | |||||||||||||||||
| Asset Turnover TTM | 0.83 | 1.08 | 0.86 | 0.84 | 0.69 | 1.27 | 1.16 | 1.14 | 0.95 | 0.92 | 1.13 | 1.01 | |||||
| Days Sales Outstanding TTM | 26.81 | 23.19 | 21.04 | 27.27 | 25.71 | 15.51 | 7.67 | 8.54 | 9.40 | 11.55 | 8.71 | 13.77 | |||||
| Receivables Turnover TTM | 13.61 | 15.74 | 17.35 | 13.38 | 14.20 | 23.54 | 47.57 | 42.76 | 38.84 | 31.59 | 41.88 | 26.51 | |||||
Per Share Metrics | |||||||||||||||||
| Diluted EPS TTM | -1.44 | -1.71 | -2.06 | -1.56 | -1.58 | -1.31 | -2.22 | -1.90 | -3.73 | -6.78 | -11.14 | -12.87 | |||||
| Free Cash Flow Per Share TTM | -0.97 | -1.36 | -1.73 | -1.06 | -1.29 | -1.69 | -2.64 | -1.98 | -3.61 | -5.04 | -10.46 | -10.89 | |||||
| Dividend Per Share TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Margin Metrics | |||||||||||||||||
| Gross Profit Margin TTM | 61.89% | 61.79% | 60.44% | 55.74% | 55.93% | 58.73% | 60.00% | 61.80% | 60.08% | 58.90% | 59.93% | 59.06% | |||||
| Operating Profit Margin TTM | -107.89% | -115.45% | -114.05% | -94.25% | -98.88% | -77.28% | -74.32% | -85.73% | -96.24% | -120.30% | -125.32% | -132.27% | |||||
| Net Profit Margin TTM | -121.79% | -127.70% | -121.37% | -98.77% | -99.49% | -76.82% | -74.09% | -86.19% | -85.90% | -117.06% | -98.42% | -106.27% | |||||
Growth Metrics | |||||||||||||||||
| Net Revenue Growth (1Y) | 45.21% | 33.77% | 16.05% | 18.76% | 2.65% | 9.47% | 8.91% | 0.54% | -9.23% | -17.70% | -13.87% | -11.93% | |||||
| Net Income Growth (1Y) | 77.77% | 122.37% | 90.10% | 36.09% | 18.89% | -28.17% | -18.02% | -18.45% | -35.77% | -22.62% | -43.04% | -38.72% | |||||
| EPS Growth (1Y) | -8.64% | 30.61% | -7.11% | -17.88% | -57.76% | -80.71% | -80.09% | -85.24% | -76.18% | -66.79% | -56.99% | -56.52% | |||||
Valuation Metrics | |||||||||||||||||
| P/E TTM | -0.32 | -0.69 | -0.99 | -1.99 | -2.01 | -2.18 | -1.93 | -1.37 | -0.60 | -0.71 | -1.12 | -0.37 | |||||
| P/B TTM | -2.02 | -15.17 | -14.00 | 13.42 | 6.27 | 5.56 | 2.71 | 2.25 | 1.13 | 19.16 | 36.91 | 124.93 | |||||
| P/S TTM | 0.38 | 0.88 | 1.20 | 1.96 | 1.99 | 1.67 | 1.43 | 1.18 | 0.51 | 0.83 | 1.10 | 0.40 | |||||
| Market Cap | 8.05M | 17.27M | 20.86M | 33.99M | 28.72M | 24.50M | 21.54M | 17.27M | 7.17M | 11.15M | 15.17M | 5.75M | |||||
| Enterprise Value | 14.41M | 22.93M | 27.70M | 39.67M | 32.29M | 22.15M | 15.28M | 10.95M | 263.97K | 8.54M | 13.53M | 4.76M | |||||
Calculated Values | |||||||||||||||||
| Free Cash Flow TTM | -17.07M | -19.88M | -17.77M | -11.61M | -11.75M | -14.51M | -13.26M | -13.07M | -11.64M | -11.64M | -12.75M | -13.04M | |||||
| Net Debt | 6.36M | 5.66M | 6.85M | 5.69M | 3.57M | -2.34M | -6.26M | -6.31M | -6.90M | -2.61M | -1.64M | -988.00K | |||||
Per-Share and Margin | |||||||||||||||||
| EPS TTM | |||||||||||||||||
| Adjusted EPS TTM | |||||||||||||||||
| Cash Flow Per Share TTM | |||||||||||||||||
| Pretax Margin TTM | |||||||||||||||||
| Stock Comp to Revenue TTM | |||||||||||||||||
Turnover Ratios and Averages | |||||||||||||||||
| Average Assets | |||||||||||||||||
| Average Equity | |||||||||||||||||
| Average Inventory | |||||||||||||||||
| Average Receivables | |||||||||||||||||
| Average Accounts Payables | |||||||||||||||||
| Inventory Turnover TTM | |||||||||||||||||
| Payables Turnover TTM | |||||||||||||||||
| Days Inventory Outstanding TTM | |||||||||||||||||
| Days Payables Outstanding TTM | |||||||||||||||||
| Cash Conversion Cycle TTM | |||||||||||||||||
| Working Capital to Revenue | |||||||||||||||||
| Deferred Revenue to Revenue | |||||||||||||||||
Growth Rates | |||||||||||||||||
| Total Assets Growth (1Y) | |||||||||||||||||
| Total Assets Growth (3Y) | |||||||||||||||||
| Total Assets Growth (5Y) | |||||||||||||||||
| Dividends Paid Growth (1Y) | |||||||||||||||||
| Dividends Paid Growth (3Y) | |||||||||||||||||
| Dividends Paid Growth (5Y) | |||||||||||||||||
| EPS Growth (3Y) | |||||||||||||||||
| EPS Growth (5Y) | |||||||||||||||||
| Net Income Growth (3Y) | |||||||||||||||||
| Net Income Growth (5Y) | |||||||||||||||||
| Net Profit Margin Growth (1Y) | |||||||||||||||||
| Net Profit Margin Growth (3Y) | |||||||||||||||||
| Net Profit Margin Growth (5Y) | |||||||||||||||||
| Net Revenue Growth (3Y) | |||||||||||||||||
| Net Revenue Growth (5Y) | |||||||||||||||||
| Deferred Revenue Growth (1Y) | |||||||||||||||||
| Retained Earnings Growth (1Y) | |||||||||||||||||
Credit, Liquidity, Returns, Payout | |||||||||||||||||
| Cash Ratio | |||||||||||||||||
| Net Working Capital | |||||||||||||||||
| Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to Equity | |||||||||||||||||
| Altman A | |||||||||||||||||
| Altman B | |||||||||||||||||
| Altman C | |||||||||||||||||
| Altman D | |||||||||||||||||
| Altman E | |||||||||||||||||
| Altman Z-Score | |||||||||||||||||
| ROA TTM | |||||||||||||||||
| ROE TTM | |||||||||||||||||
| NOPAT TTM | |||||||||||||||||
| ROIC TTM | |||||||||||||||||
| Effective Tax Rate TTM | |||||||||||||||||
| Payout Ratio TTM | |||||||||||||||||
| Dilution Ratio | |||||||||||||||||
| Retained Earnings to Equity | |||||||||||||||||
| Treasury Stock to Equity | |||||||||||||||||
| Treasury Stock Change (1Y) | |||||||||||||||||
| Accrued to Current Liabilities | |||||||||||||||||
| NCAV | |||||||||||||||||
| NCAV Per Share TTM | |||||||||||||||||
Valuation Ratios | |||||||||||||||||
| P/CF TTM | |||||||||||||||||
| PEG Ratio | |||||||||||||||||
| Dividend Yield TTM | |||||||||||||||||
| Free Cash Flow Yield TTM | |||||||||||||||||
| EV EBITDA TTM | |||||||||||||||||
| EV EBIT TTM | |||||||||||||||||
| EV Revenue TTM | |||||||||||||||||
| EV FCF TTM | |||||||||||||||||
| Stock Compensation TTM | |||||||||||||||||
| Adjusted Net Income TTM | |||||||||||||||||
| Billings TTM | |||||||||||||||||
| Total Debt | |||||||||||||||||
| Invested Capital | |||||||||||||||||
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Vivos Therapeutics, Inc. (VVOS) — SEC Financial Statements & Analysis
Vivos Therapeutics, Inc. (VVOS) is a surgical & medical instruments & apparatus company, incorporated in DE. Vivos Therapeutics, Inc. trades on Nasdaq as: VVOS. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Vivos Therapeutics, Inc. reported a 45.21% year-over-year revenue growth, a Gross Profit Margin of 61.89% (TTM), a Debt-to-Equity ratio of -7.06x, a Price-to-Sales (P/S) ratio of 0.38x (TTM), a Price-to-Book (P/B) ratio of -2.02x (TTM), at a market cap of $8.05M. Figures below are sourced from SEC EDGAR, as-filed.
- Net Revenue TTM Growth 1Y
- 45.21%
- Gross Profit Margin TTM
- 61.89%
- Debt To Equity
- -7.06x
- P/S TTM
- 0.38x
- P/B TTM
- -2.02x
- Market Cap
- $8.05M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Vivos Therapeutics, Inc. in?
Vivos Therapeutics, Inc. (VVOS) operates in the Surgical & Medical Instruments & Apparatus industry.
What is VVOS's market cap?
Vivos Therapeutics, Inc. (VVOS) has a market capitalization of $8.05M as of 2026-06-30.
What exchange does VVOS trade on?
Vivos Therapeutics, Inc. (VVOS) trades on the Nasdaq.
Where is Vivos Therapeutics, Inc. incorporated?
Vivos Therapeutics, Inc. is incorporated in DE.